Estimated Savings from International Reference Pricing for Prescription Drugs

Andrew W. Mulcahy, Daniel Schwam, Preethi Rao, Stephanie Rennane, Kanaka Shetty

ResearchPosted on rand.org Dec 9, 2021Published in: JAMA, Volume 326, Number 17, pages 1744–745 (2021). doi: 10.1001/jama.2021.13338

Tying U.S. drug prices to an international reference price would have lowered 2020 US spending on selected prescription drugs by 52.3% or $83.5 billion, from $159.9 billion at US net prices to $76.3 billion.

Read More

Topics

Document Details

  • Copyright: American Medical Association
  • Publisher: JAMA Network
  • Availability: Non-RAND
  • Year: 2021
  • Pages: 2
  • Document Number: EP-68785

Research conducted by

This publication is part of the RAND external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.